Latest Insider Transactions at Madrigal Pharmaceuticals, Inc. (MDGL)
This section provides a real-time view of insider transactions for Madrigal Pharmaceuticals, Inc. (MDGL). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of MADRIGAL PHARMACEUTICALS, INC. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of MADRIGAL PHARMACEUTICALS, INC.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 12
2024
|
Robert E. Waltermire Senior VP, Chief Pharma Dev. |
BUY
Exercise of conversion of derivative security
|
Direct |
2,000
+21.05%
|
$174,000
$87.92 P/Share
|
|
Jun 11
2024
|
Fred B Craves Director |
SELL
Bona fide gift
|
Indirect |
45,852
-80.35%
|
-
|
|
Jun 11
2024
|
Fred B Craves Director |
SELL
Bona fide gift
|
Direct |
39,000
-9.43%
|
-
|
|
May 21
2024
|
Robert E. Waltermire Senior VP, Chief Pharma Dev. |
SELL
Open market or private sale
|
Direct |
1,036
-15.85%
|
$239,316
$231.34 P/Share
|
|
May 14
2024
|
Fred B Craves Director |
SELL
Open market or private sale
|
Direct |
22,489
-0.53%
|
$4,835,135
$215.4 P/Share
|
|
May 14
2024
|
Fred B Craves Director |
BUY
Exercise of conversion of derivative security
|
Direct |
22,489
+2.55%
|
$2,293,878
$102.76 P/Share
|
|
Apr 08
2024
|
Paul A Friedman |
SELL
Open market or private sale
|
Direct |
26,270
-1.87%
|
$6,436,150
$245.85 P/Share
|
|
Apr 08
2024
|
Paul A Friedman |
BUY
Exercise of conversion of derivative security
|
Direct |
26,270
+11.03%
|
$236,430
$9.45 P/Share
|
|
Apr 08
2024
|
Rebecca Taub Pres., R&D, and CMO |
SELL
Open market or private sale
|
Direct |
2,676
-0.1%
|
$658,296
$246.17 P/Share
|
|
Apr 08
2024
|
Rebecca Taub Pres., R&D, and CMO |
BUY
Exercise of conversion of derivative security
|
Direct |
2,676
+0.58%
|
$24,084
$9.45 P/Share
|
|
Apr 05
2024
|
Paul A Friedman |
SELL
Open market or private sale
|
Direct |
27,613
-1.95%
|
$6,709,959
$243.19 P/Share
|
|
Apr 05
2024
|
Paul A Friedman |
BUY
Exercise of conversion of derivative security
|
Direct |
27,613
+11.46%
|
$248,517
$9.45 P/Share
|
|
Apr 05
2024
|
Rebecca Taub Pres., R&D, and CMO |
SELL
Open market or private sale
|
Direct |
27,506
-0.96%
|
$6,656,452
$242.86 P/Share
|
|
Apr 05
2024
|
Rebecca Taub Pres., R&D, and CMO |
BUY
Exercise of conversion of derivative security
|
Direct |
27,506
+5.35%
|
$247,554
$9.45 P/Share
|
|
Apr 04
2024
|
Paul A Friedman |
SELL
Open market or private sale
|
Direct |
18,710
-1.19%
|
$4,565,240
$244.68 P/Share
|
|
Apr 04
2024
|
Paul A Friedman |
BUY
Exercise of conversion of derivative security
|
Direct |
18,710
+8.38%
|
$168,390
$9.45 P/Share
|
|
Apr 04
2024
|
Rebecca Taub Pres., R&D, and CMO |
SELL
Open market or private sale
|
Direct |
18,537
-0.49%
|
$4,523,028
$244.5 P/Share
|
|
Apr 04
2024
|
Rebecca Taub Pres., R&D, and CMO |
BUY
Exercise of conversion of derivative security
|
Direct |
18,537
+3.74%
|
$166,833
$9.45 P/Share
|
|
Apr 03
2024
|
Paul A Friedman |
SELL
Open market or private sale
|
Direct |
27,407
-2.66%
|
$6,687,308
$244.37 P/Share
|
|
Apr 03
2024
|
Paul A Friedman |
BUY
Exercise of conversion of derivative security
|
Direct |
27,407
+11.39%
|
$246,663
$9.45 P/Share
|
|
Apr 03
2024
|
Rebecca Taub Pres., R&D, and CMO |
SELL
Open market or private sale
|
Direct |
27,845
-1.16%
|
$6,794,180
$244.4 P/Share
|
|
Apr 03
2024
|
Rebecca Taub Pres., R&D, and CMO |
BUY
Exercise of conversion of derivative security
|
Direct |
27,845
+5.41%
|
$250,605
$9.45 P/Share
|
|
Apr 02
2024
|
James M Daly Director |
SELL
Open market or private sale
|
Direct |
10,912
-27.97%
|
$2,673,440
$245.69 P/Share
|
|
Apr 02
2024
|
James M Daly Director |
BUY
Exercise of conversion of derivative security
|
Direct |
10,912
+47.4%
|
$1,145,760
$105.08 P/Share
|
|
Apr 02
2024
|
Kenneth Bate Director |
SELL
Open market or private sale
|
Direct |
11,212
-24.5%
|
$2,758,152
$246.16 P/Share
|
|
Apr 02
2024
|
Kenneth Bate Director |
BUY
Exercise of conversion of derivative security
|
Direct |
11,212
+47.46%
|
$1,177,260
$105.08 P/Share
|
|
Apr 01
2024
|
Richard S Levy Director |
SELL
Open market or private sale
|
Direct |
11,000
-10.99%
|
$2,860,000
$260.36 P/Share
|
|
Apr 01
2024
|
Richard S Levy Director |
BUY
Exercise of conversion of derivative security
|
Direct |
11,000
+23.31%
|
$649,000
$59.21 P/Share
|
|
Apr 01
2024
|
James M Daly Director |
SELL
Open market or private sale
|
Direct |
21,577
-24.39%
|
$5,610,020
$260.94 P/Share
|
|
Apr 01
2024
|
James M Daly Director |
BUY
Exercise of conversion of derivative security
|
Direct |
21,577
+27.51%
|
$2,200,854
$102.76 P/Share
|
|
Apr 01
2024
|
Kenneth Bate Director |
SELL
Open market or private sale
|
Direct |
21,277
-24.11%
|
$5,532,020
$260.91 P/Share
|
|
Apr 01
2024
|
Kenneth Bate Director |
BUY
Exercise of conversion of derivative security
|
Direct |
21,277
+28.2%
|
$1,510,667
$71.66 P/Share
|
|
Jan 23
2024
|
Carole Huntsman Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
3,639
+24.08%
|
-
|
|
Jan 23
2024
|
Robert E. Waltermire Senior VP, Chief Pharma Dev. |
BUY
Grant, award, or other acquisition
|
Direct |
1,419
+17.84%
|
-
|
|
Jan 23
2024
|
Rebecca Taub Pres., R&D, and CMO |
BUY
Grant, award, or other acquisition
|
Direct |
5,786
+21.77%
|
-
|
|
Jan 23
2024
|
Alex G. Howarth Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
4,803
+20.4%
|
-
|
|
Jan 23
2024
|
William John Sibold President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
12,250
+16.44%
|
-
|
|
Jan 23
2024
|
Brian Joseph Lynch SVP and General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
3,639
+17.06%
|
-
|
|
Jan 16
2024
|
Brian Joseph Lynch SVP and General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
949
-6.33%
|
$230,607
$243.92 P/Share
|
|
Jan 16
2024
|
Robert E. Waltermire Senior VP, Chief Pharma Dev. |
SELL
Payment of exercise price or tax liability
|
Direct |
550
-9.71%
|
$133,650
$243.92 P/Share
|
|
Jan 16
2024
|
Rebecca Taub Pres., R&D, and CMO |
SELL
Payment of exercise price or tax liability
|
Direct |
1,546
-9.34%
|
$375,678
$243.92 P/Share
|
|
Jan 16
2024
|
Alex G. Howarth Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,067
-7.11%
|
$259,281
$243.92 P/Share
|
|
Dec 15
2023
|
Robert E. Waltermire Senior VP, Chief Pharma Dev. |
SELL
Open market or private sale
|
Direct |
2,000
-14.02%
|
$476,000
$238.5 P/Share
|
|
Dec 15
2023
|
Robert E. Waltermire Senior VP, Chief Pharma Dev. |
BUY
Exercise of conversion of derivative security
|
Direct |
2,000
+20.69%
|
$174,000
$87.92 P/Share
|
|
Dec 14
2023
|
Robert E. Waltermire Senior VP, Chief Pharma Dev. |
SELL
Open market or private sale
|
Direct |
2,000
-14.02%
|
$464,000
$232.5 P/Share
|
|
Dec 14
2023
|
Robert E. Waltermire Senior VP, Chief Pharma Dev. |
BUY
Exercise of conversion of derivative security
|
Direct |
2,000
+20.69%
|
$174,000
$87.92 P/Share
|
|
Dec 14
2023
|
Baker Bros. Advisors LP |
BUY
Open market or private purchase
|
Indirect |
20,633
+0.24%
|
$4,704,324
$228.37 P/Share
|
|
Dec 13
2023
|
Baker Bros. Advisors LP |
BUY
Open market or private purchase
|
Indirect |
81,159
+0.47%
|
$17,854,980
$220.73 P/Share
|
|
Dec 13
2023
|
Robert E. Waltermire Senior VP, Chief Pharma Dev. |
SELL
Open market or private sale
|
Direct |
2,500
-16.68%
|
$562,500
$225.5 P/Share
|
|
Dec 13
2023
|
Robert E. Waltermire Senior VP, Chief Pharma Dev. |
BUY
Exercise of conversion of derivative security
|
Direct |
2,500
+23.44%
|
$217,500
$87.92 P/Share
|